RELMADA THERAPEUTICS, INC. RLMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-10.21
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$57.4M | — | — | $86.5M |
| 2024 | — | -$80.0M | — | — | $35.5M |
| 2023 | — | -$98.8M | — | — | $85.4M |
| 2022 | — | -$157.0M | — | — | $140.4M |
| 2021 | — | -$125.8M | — | — | $208.3M |
| 2020 | — | -$59.5M | — | — | $105.6M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.21 (distress)
- Working capital / assets 0.931
- Retained earnings / assets -7.428
- EBIT / assets -0.629
- Equity / liabilities 11.548
Source: SEC EDGAR filings · CIK 0001553643 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.